Oncology nurse pride How Have Your Family Experiences With Cancer Impacted Your Decision to Become an Oncology Nurse? June 09, 2017
Genetics & genomics The Story of Henrietta Lacks Sheds Light on Ethical Considerations in Genetic Testing April 28, 2017
Topic Prostate cancer Cancer research Less Sleep May Increase Risk of Death From Prostate Cancer Men younger than 65 years who sleep less than six hours per night have an increased risk of death from prostate cancer, according to the results of a study presented at the American Association for Cancer Research 2017 annual meeting. June 28, 2017 Prostate cancer Revised USPSTF Draft Guidelines Recommend Individual Prostate Cancer Screening Decisions The U.S. Preventive Services Task Force (USPSTF) has issued new draft revisions for prostate cancer screening guidelines. In the draft, the USPSTF has changed its previous stance on prostate-specific antigen (PSA) screening tests for men aged 55–69. The drafted guidelines now recommend PSA screening tests for men aged 55–69 based on individual assessment. The USPSTF has upgraded its recommendation from D to C, encouraging physicians to discuss with their patients whether PSA testing is right for them. The USPSTF still recommends against PSA screening tests in patients aged 70 or older. April 13, 2017 American Cancer Society (ACS) Cancer Deaths Fall 25% Since 1991 Research, treatment, and technology surges throughout the 1990s have led to a 25% reduction in cancer mortality rates since 1991, according to the American Cancer Society’s (ACS’s) latest Cancer Statistics, 2017, report (Siegel, Miller, & Jemal, 2016). The decline in cancer-related deaths accounts for more than 2.1 million lives saved between 1991 and 2014. January 29, 2017 Cancer risk factors Increasing Adult BMI May Raise Risk of Fatal Prostate Cancer Men whose body mass index (BMI) increases to obesity during adulthood may have a higher risk of fatal prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. January 29, 2017 Cancer screening Metastatic Prostate Cancer Increasing in United States The number of new U.S. cases of metastatic prostate cancer increased by 72% from 2004–2013, according to a new study published in Prostate Cancer and Prostatic Diseases. September 06, 2016 Oncology drug research New Class of Drugs Shows Promise in Treatment-Resistant Prostate Cancer Researchers in the United Kingdom are looking at a new class of drugs that attacks cancer indirectly through a network of signals, which may prevent or overcome drug resistance. The findings of the study were published in Cancer Research. July 26, 2016 Prostate cancer Prostate Radiotherapy May Increase Bladder Cancer Risk Patients with prostate cancer who undergo radiation treatment, especially brachytherapy, may be at increased risk of bladder cancer more than 10 years later, according to the results of a new study presented at the American Urological Association annual meeting. July 12, 2016 Oncology drug research FDA Approves Enzalutamide for Patients With Prostate Cancer Who Have not Received Prior Chemotherapy On September 10, 2014, the U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer. September 11, 2014 Prostate cancer Prostate Cancer Nursing Management Is Critical to Quality Care Prostate cancer nursing management must be well understood because prostate cancer is the second most common cancer in men after skin cancer; however, prostate cancer can be successfully treated. According to the American Cancer Society, more than two million men in the United States are prostate cancer survivors. September 18, 2013 Clinical practice FDA Approves Xofigo for Castration-Resistant Prostate Cancer On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. May 21, 2013 Cancer screening Controversial Cancer Screening Guidelines Can Help Nurses Start the Screening Conversation The controversy over prostate cancer screening guidelines heated up last November August 01, 2012 Trending Topics Safety Standards Research Treatments ONS Congress Clinical practice Immunotherapy U.S. Food and Drug Administration (FDA) Cancer research Nursing education View All Topics
Cancer research Less Sleep May Increase Risk of Death From Prostate Cancer Men younger than 65 years who sleep less than six hours per night have an increased risk of death from prostate cancer, according to the results of a study presented at the American Association for Cancer Research 2017 annual meeting. June 28, 2017
Prostate cancer Revised USPSTF Draft Guidelines Recommend Individual Prostate Cancer Screening Decisions The U.S. Preventive Services Task Force (USPSTF) has issued new draft revisions for prostate cancer screening guidelines. In the draft, the USPSTF has changed its previous stance on prostate-specific antigen (PSA) screening tests for men aged 55–69. The drafted guidelines now recommend PSA screening tests for men aged 55–69 based on individual assessment. The USPSTF has upgraded its recommendation from D to C, encouraging physicians to discuss with their patients whether PSA testing is right for them. The USPSTF still recommends against PSA screening tests in patients aged 70 or older. April 13, 2017
American Cancer Society (ACS) Cancer Deaths Fall 25% Since 1991 Research, treatment, and technology surges throughout the 1990s have led to a 25% reduction in cancer mortality rates since 1991, according to the American Cancer Society’s (ACS’s) latest Cancer Statistics, 2017, report (Siegel, Miller, & Jemal, 2016). The decline in cancer-related deaths accounts for more than 2.1 million lives saved between 1991 and 2014. January 29, 2017
Cancer risk factors Increasing Adult BMI May Raise Risk of Fatal Prostate Cancer Men whose body mass index (BMI) increases to obesity during adulthood may have a higher risk of fatal prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. January 29, 2017
Cancer screening Metastatic Prostate Cancer Increasing in United States The number of new U.S. cases of metastatic prostate cancer increased by 72% from 2004–2013, according to a new study published in Prostate Cancer and Prostatic Diseases. September 06, 2016
Oncology drug research New Class of Drugs Shows Promise in Treatment-Resistant Prostate Cancer Researchers in the United Kingdom are looking at a new class of drugs that attacks cancer indirectly through a network of signals, which may prevent or overcome drug resistance. The findings of the study were published in Cancer Research. July 26, 2016
Prostate cancer Prostate Radiotherapy May Increase Bladder Cancer Risk Patients with prostate cancer who undergo radiation treatment, especially brachytherapy, may be at increased risk of bladder cancer more than 10 years later, according to the results of a new study presented at the American Urological Association annual meeting. July 12, 2016
Oncology drug research FDA Approves Enzalutamide for Patients With Prostate Cancer Who Have not Received Prior Chemotherapy On September 10, 2014, the U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer. September 11, 2014
Prostate cancer Prostate Cancer Nursing Management Is Critical to Quality Care Prostate cancer nursing management must be well understood because prostate cancer is the second most common cancer in men after skin cancer; however, prostate cancer can be successfully treated. According to the American Cancer Society, more than two million men in the United States are prostate cancer survivors. September 18, 2013
Clinical practice FDA Approves Xofigo for Castration-Resistant Prostate Cancer On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. May 21, 2013
Cancer screening Controversial Cancer Screening Guidelines Can Help Nurses Start the Screening Conversation The controversy over prostate cancer screening guidelines heated up last November August 01, 2012
